Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Number of holders
-
40
-
Total 13F principal, excl. options
-
532,460,742
-
Principal change
-
-22,126,258
-
Total reported value, excl. options
-
$739,286,875
-
Value change
-
-$47,139,012
-
Number of buys
-
23
-
Number of sells
-
-12
-
Price
-
$1.38
Significant Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q3 2021
47 filings reported holding 10806XAB8 - BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q3 2021.
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 has 40 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $532,460,742 of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($114,950,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($82,696,000 of principal), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($80,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($41,500,000 of principal), BANK OF AMERICA CORP /DE/ ($34,995,000 of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($21,000,000 of principal), STATE STREET CORP ($16,605,000 of principal), CALAMOS ADVISORS LLC ($16,000,000 of principal), Polygon Management Ltd. ($15,000,000 of principal), and Aequim Alternative Investments LP ($14,800,000 of principal).
This table shows the top 40 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.